Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Working capital
Funding the working capital the company needs to carry projects between billing milestones.
Inorganic growth through acquisitions
Pursuing acquisitions and other inorganic growth opportunities.
General corporate purposes
The balance of the proceeds is set aside for the company's general corporate requirements.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
No peer comparisons added yet.
Fabtech Technologies Limited is a Mumbai based engineering company that designs and builds the physical facilities in which medicines are made. It supplies turnkey projects to the pharmaceutical, biotechnology and healthcare industries, taking a project from design and engineering through procurement, manufacturing, installation, testing and commissioning. Its core work is cleanroom construction, modular wall and ceiling systems, heating and ventilation systems, and process equipment, all of which must meet the regulatory standards that govern drug manufacturing. The company was incorporated in 2018 and operates as part of the wider Fabtech group. It works on an asset light basis, keeping in house design and software capability while relying on group entities and outside suppliers for a good deal of the equipment it installs. Its order book is spread across a range of geographies, clients and project types, and it has executed work for customers in more than sixty countries across the Middle East, Africa, Asia, Europe and the Americas. It employed roughly 185 permanent staff at the time of the offer. Revenue rose from about 200 crore rupees in FY2023 to roughly 336 crore rupees in FY2025, with profit after tax climbing from about 22 crore to 46 crore over the same period, and returns on equity in the high twenties. The business is project driven, so its results depend on winning and completing a relatively small number of large contracts. Only a modest fraction of the proposals it submits convert into orders, an order book is not a guarantee of revenue if a project slips or is cancelled, and a lapse in quality on a regulated facility would carry both commercial and reputational cost.
No anchor investors added yet.
Source: RHP • Analysis provided for informational purposes
Last Updated: 13 July 2026, 4:47 AM
End to end turnkey delivery
The company handles a pharmaceutical facility from design and engineering right through to installation and testing, so a client can place a single contract rather than coordinate several specialist vendors.
Asset light operating model
It keeps design, software and project management in house while outsourcing much of the heavy manufacturing, which limits the capital tied up in plant and keeps returns on equity high.
Order book spread across markets and clients
Work is drawn from customers in more than sixty countries and across several project types, so the business is not tied to the fortunes of one region or one buyer.
Track record on regulated facilities
Drug manufacturing plants must satisfy strict international standards, and a record of delivering facilities that pass those inspections is itself a barrier to newer competitors.
Growing profitability
Revenue and profit have both risen sharply over the three years to FY2025, with profit after tax roughly doubling, and margins have held up as the business has scaled.
Revenue concentrated in a few large projects
A significant share of income comes from a small number of contracts, so the loss, delay or cancellation of one of them would leave a visible hole in the results.
Order book is not assured revenue
Contracts in hand can be deferred, rescoped or cancelled by the customer, so the reported order book should not be read as income the company is certain to earn.
Low conversion of proposals into orders
Only a small proportion of the bids the company submits turn into signed contracts, which makes the pace of future growth harder to predict.
Fabtech Technologies Limited
715, Janki Centre, Off Veera Desai Road, Andheri West, Mumbai 400053, Maharashtra, India
View on Maps →No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Dependence on group entities for equipment
A meaningful part of the equipment installed on projects is procured from promoter group companies, so the terms of those related party dealings matter to margins.
Short operating history and negative cash flows
The company was incorporated only in 2018 and has reported negative operating cash flows in the past, which is common in project businesses but leaves less of a record to judge it by.